The strong demand for COVID-19 testing has significantly increased Aegis Toxicology Sciences Corp.'s revenue, leading to improved cash flow generation. As a result of dramatically improved operating performance, liquidity risks have eased, and we expect the company to generate significant positive free cash flow through at least 2021 (and possibly longer). We are affirming our 'B-' issuer credit rating. At the same time, we are revising the rating outlook to positive from negative. The positive outlook reflects our view that demand for Aegis's testing services will remain strong over the next 12 months due to the coronavirus pandemic. However, it also reflects some risk to our base case assumption that the company will use cash flow generation over this period
